bind19
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT03265106)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bind19
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03156101 | Phase 1/Phase 2 (Phase 2) | Mar 2, 2017 | Shenzhen BinDeBio Ltd., Zhengzhou University |
| NCT03265106 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | Fudan University, Shenzhen BinDeBio Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shenzhen BinDeBio Ltd. | For profit | 2 | 2 | 1 | 2016 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Zhengzhou University | Academic/Hospital | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1